ARTICLE | Clinical News
Isotechnika ISA247 Phase III results
April 26, 2005 12:50 AM UTC
Isotechnika (TSE:ISA) said blinded data from 200 psoriasis patients treated for 12 weeks in the ongoing Phase III SPIRIT trial showed that ISA247 reduced PASI scores compared with placebo. The primary...